EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer
Serrano, Maria J. (Universidad of Granada. Departamento de Medicina Legal)
Ortega, Francisco G. (Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica)
Álvarez-Cubero, María Jesús (Universidad de Granada. Departamento de Medicina Legal)
Nadal Rios, Rosa (Hospital de Barcelona)
Sanchez-Rovira, Pedro (Universidad de Jaén)
Salido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques)
Rodríguez, María (Institut Hospital del Mar d'Investigacions Mèdiques)
García-Puche, José Luis (Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica)
Delgado-Rodríguez, Miguel (Universidad de Jaén)
Solé, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
García, Maria A. (Complejo Hospitalario Universitario de Granada)
Perán, Macarena (Universidad de Granada. Instituto de Biopatología y Medicina Regenerativa)
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Marchal, Juan A. (Universidad de Granada. Departamento de Anatomía y Embriología Humana)
Lorente, Jose A. (Universidad de Granada. Departamento de Medicina Legal)
Universitat Autònoma de Barcelona

Date:	2014
Abstract:	Circulating tumor cells (CTCs) are frequently associated with epithelialmesenchymal transition (EMT). The objective of this study was to detect EMT phenotype through Vimentin (VIM) and Slug expression in cytokeratin (CK)-negative CTCs in non-metastatic breast cancer patients and to determine the importance of EGFR in the EMT phenomenon. In CK-negative CTCs samples, both VIM and Slug markers were co-expressed in the most of patients. Among patients EGFR+, half of them were positive for these EMT markers. Furthermore, after a systemic treatment 68% of patients switched from CK- to CK+ CTCs. In our experimental model we found that activation of EGFR signaling by its ligand on MCF-7 cells is sufficient to increase EMT phenotypes, to inhibit apoptotic events and to induce the loss of CK expression. The simultaneous detection of both EGFR and EMT markers in CTCs may improve prognostic or predictive information in patients with operable breast cancer.
Grants:	Instituto de Salud Carlos III PI10-02295
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Breast Cancer ; Circulating Tumor Cells ; EGFR ; Epithelial-Mesenchymal Transition ; Vimentin ; Slug ; Bcl-2 ; Apoptosis
Published in:	Oncotarget, Vol. 5 (july 2014) , p. 7486-7497, ISSN 1949-2553

DOI: 10.18632/oncotarget.2217
PMID: 25277187

12 p, 2.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles